Biologics now account for half the products currently in Phase II and Phase III clinical trials.
FORBES: Magazine Article
The GPA noted in its commentary on the New York Times article that many companies who are developing biosimilar products also manufacture branded biologics.
FORBES: Gamekeeper or Poacher? - Big Pharma's Stance on Biosimilars
应用推荐
模块上移
模块下移
不移动